Q-LINE BIOTECH LIMITED Fair Value
QLINE · Healthcare · Current price ₹635
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹372 | 26% ROE fading to 13% over ~10 yrs, on ₹209 book |
| Relative P/E | ₹1,505 | EPS × 43.9 peer-median P/E |
| Graham floor | ₹401 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is Q-LINE BIOTECH LIMITED undervalued?
DocStoX estimates the fair value of Q-LINE BIOTECH LIMITED at ₹695 per share, versus the current market price of ₹635. That puts the stock about +9.5% below our fair-value estimate, which we read as "Fairly Valued". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹372), Relative P/E (₹1,505), Graham floor (₹401). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹372 (bear) to ₹695 (base) to ₹1,505 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on Q-LINE BIOTECH LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.